Sign up for our daily briefing
Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Denver news in your inbox
Catch up on the most important stories affecting your hometown with Axios Denver
Des Moines news in your inbox
Catch up on the most important stories affecting your hometown with Axios Des Moines
Minneapolis-St. Paul news in your inbox
Catch up on the most important stories affecting your hometown with Axios Twin Cities
Tampa Bay news in your inbox
Catch up on the most important stories affecting your hometown with Axios Tampa Bay
Charlotte news in your inbox
Catch up on the most important stories affecting your hometown with Axios Charlotte
Photo: Artur Widak/NurPhoto via Getty Images
The Blackstone Group agreed to buy Ayumi Pharmaceutical, a Japanese maker of anti-rheumatism drugs, from Unison Capital for a reported $1 billion.
Why it's the BFD: Because it's Blackstone's first-ever buyout in Japan, and comes as many other U.S. and European private equity firms are seeking deals in a country they had spent over a decade ignoring. "We are seeing much more deal flow in Japan," said Kewsong Lee, co-CEO of The Carlyle Group, speaking last month at the SuperReturn event in Berlin. "It is the third largest economy in the world, but private-equity penetration there is much lower."